OverviewSuggest Edit

Voyager Therapeutics is a gene therapy company developing life-changing treatments for fatal and debilitating diseases of the central nervous system (CNS). The Company’s initial pipeline is focused on CNS diseases in dire need of effective new therapies, including Parkinson’s disease, a monogenic form of amyotrophic lateral sclerosis, and Friedreich’s ataxia. 

TypePublic
Founded2014
HQCambridge, MA, US
Websitevoyagertherapeutics.com
Employee Ratings2.6

Latest Updates

Employees (est.) (Dec 2019)185(+51%)
Job Openings15
Revenue (FY, 2020)$171.1 M(+64%)
Share Price (May 2022)$6.4(+6%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at Voyager Therapeutics

Michael Higgins

Michael Higgins

Interim Chief Executive Officer
Jim Geraghty

Jim Geraghty

Director
Glenn Pierce

Glenn Pierce

Interim Chief Scientific Officer
Steven Hyman

Steven Hyman

Director
Mark Levin

Mark Levin

Director
Steven Paul

Steven Paul

Director
Show more

Voyager Therapeutics Office Locations

Voyager Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
75 Sidney St
Show all (1)

Voyager Therapeutics Financials and Metrics

Voyager Therapeutics Revenue

Voyager Therapeutics's revenue was reported to be $171.13 m in FY, 2020
USD

Revenue (FY, 2020)

171.1m

Net income (FY, 2020)

36.7m

EBIT (FY, 2020)

27.4m

Market capitalization (13-May-2022)

244.8m

Closing stock price (13-May-2022)

6.4

Cash (31-Dec-2020)

104.4m

EV

144.6m
Voyager Therapeutics's current market capitalization is $244.8 m.
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Revenue

17.3m14.2m10.1m7.6m104.4m171.1m

Revenue growth, %

(18%)

General and administrative expense

9.9m13.3m19.7m33.8m36.3m35.0m

R&D expense

27.7m42.2m62.3m64.9m119.7m108.8m
Quarterly
USDQ3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020

Revenue

4.9m4.8m3.7m3.3m1.5m1.2m1.1m942.0k2.6m2.1m5.2m46.1m20.4m18.1m28.7m

General and administrative expense

2.5m3.6m2.9m3.4m4.9m4.5m4.9m7.2m11.8m6.6m9.7m8.3m8.5m10.2m8.2m

R&D expense

6.5m8.7m10.5m10.3m14.1m15.3m19.6m14.9m16.5m16.6m24.8m28.6m29.8m32.3m29.4m

Operating expense total

9.0m12.3m13.3m13.7m19.0m19.8m24.5m22.0m28.3m23.2m34.5m36.9m38.2m42.5m37.7m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Cash

31.5m46.9m86.0m104.4m

Accounts Receivable

826.0m

Prepaid Expenses

2.7m6.7m4.6m8.6m

Current Assets

195.9m178.8m171.8m162.5m304.7m197.8m
Annual
USDFY, 2015FY, 2016FY, 2017FY, 2018FY, 2019FY, 2020

Net Income

(3.8m)(40.2m)(70.7m)(88.3m)(43.6m)36.7m

Depreciation and Amortization

600.0k612.0k1.6m2.1m2.8m

Inventories

(234.0k)(847.0k)

Accounts Payable

950.0k(62.0k)470.0k(282.0k)2.6m(3.4m)
USDQ3, 2015

Financial Leverage

-3.5 x
Show all financial metrics

Voyager Therapeutics Operating Metrics

FY, 2016

Patent Applications

28

Patents Issued

157
Show all operating metrics

Voyager Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

97/100

SecurityScorecard logo

Voyager Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

40-49

out of 100

CSRHub logo

Voyager Therapeutics Online and Social Media Presence

Embed Graph

Voyager Therapeutics News and Updates

Voyager Therapeutics Reports First Quarter 2022 Financial and Operating Results

Company to present new data at the American Society for Gene and Cell Therapy (ASGCT) Annual Meeting highlighting cross-species translatability and CNS tropisms of novel TRACER™ AAV9- and AAV5-derived capsids

Voyager Therapeutics Announces Multiple Data Presentations at the American Society of Gene and Cell Therapy 2022 Annual Meeting

CAMBRIDGE, Mass., May 03, 2022 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a gene therapy company developing life-changing treatments and next-generation adeno-associated virus (AAV) capsids, today announced nine data presentations at the upcoming American Society of Gene and Ce…

Voyager Therapeutics Appoints Alfred W. Sandrock, Jr., M.D., Ph.D., as Chief Executive Officer

Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy Renowned neuroscientist brings pioneering drug development expertise and vision to emerging leader in next-generation AAV gene therapy

Thinking about buying stock in Voyager Therapeutics, Ion Geophysical, KLX Energy, Deutsche Bank, or Smart Sand?

NEW YORK, March 8, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for VYGR, IO, KLXE, DB, and SND. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Voyager Therapeutics Reports Fourth Quarter and Full Year 2021 Financial and Operating Results

License option agreement with Novartis for target-specific access to TRACER™ next-generation AAV capsids for potential use with three CNS targets plus options to access capsids for two additional targets

Voyager Therapeutics Announces License Option Agreement with Novartis for Target-Specific Access to Next-Generation TRACER™ AAV Capsids for Gene Therapy Programs

Voyager receives $54 million upfront with potential option exercise fees and milestone payments of up to $1.7 billion plus product sales-based royalties
Show more

Voyager Therapeutics Blogs

Voyager Therapeutics’ Novel Capsids Demonstrate Robust Delivery Across the Blood Brain Barrier, Widespread CNS Transduction in Non-Human Primates

Data to be presented at the 24 th Annual Meeting of the American Society of Gene and Cell Therapy show up to 1000-fold higher transgene expression in the brain compared with conventional AAV gene therapy following IV administration CAMBRIDGE, Mass. , May 11, 2021 (GLOBE NEWSWIRE) -- Voyager

Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates

Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates Content Import Thu, 02/25/2021 - 16:02 Voyager Therapeutics Announces Fourth Quarter and Full Year 2020 Financial Results and Corporate Updates Feb 25, 2021 …

Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference

Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor Conference Content Import Thu, 02/18/2021 - 16:02 Voyager Therapeutics to Report Fourth Quarter and Full Year 2020 Financial Results and Participate in Upcoming Investor …

Voyager Therapeutics Announces Third Quarter 2020 Financial Results and Corporate Updates

CAMBRIDGE, Mass. , Nov. 09, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR) today reported its third quarter 2020 financial results, program progress and corporate updates. “During the third quarter, we took important steps to advance our lead programs for Parkinson’s disease and

Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program

Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program Content Import Mon, 10/12/2020 - 16:01 Voyager Therapeutics Provides Regulatory Update on VY-HTT01 Program Oct 12, 2020 This release is a backfill from a News Wire General …

Voyager Therapeutics Appoints Nancy Vitale to its Board of Directors

CAMBRIDGE, Mass. , Sept. 15, 2020 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company focused on developing life-changing treatments for severe neurological diseases, today announced the addition of Nancy Vitale as an independent director to its
Show more

Voyager Therapeutics Frequently Asked Questions

  • When was Voyager Therapeutics founded?

    Voyager Therapeutics was founded in 2014.

  • Who are Voyager Therapeutics key executives?

    Voyager Therapeutics's key executives are Michael Higgins, Jim Geraghty and Glenn Pierce.

  • How many employees does Voyager Therapeutics have?

    Voyager Therapeutics has 185 employees.

  • What is Voyager Therapeutics revenue?

    Latest Voyager Therapeutics annual revenue is $171.1 m.

  • What is Voyager Therapeutics revenue per employee?

    Latest Voyager Therapeutics revenue per employee is $925 k.

  • Who are Voyager Therapeutics competitors?

    Competitors of Voyager Therapeutics include Taysha Gene Therapies, Watchmaker Genomics and New England Biolabs.

  • Where is Voyager Therapeutics headquarters?

    Voyager Therapeutics headquarters is located at 75 Sidney St, Cambridge.

  • Where are Voyager Therapeutics offices?

    Voyager Therapeutics has an office in Cambridge.

  • How many offices does Voyager Therapeutics have?

    Voyager Therapeutics has 1 office.